A pliable ERα cistrome evades therapy

The transcription factor oestrogen receptor alpha (ERα) has long been targeted for therapeutic benefit in cancer, but drug resistance can emerge through a multitude of mechanisms. A study now reveals how the ERα cistrome can become reprogrammed to confer resistance to tamoxifen in breast cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: A reprogrammed ERα cistrome that bypasses tamoxifen therapy in breast cancer.


  1. 1.

    Darnell, J. E. Jr. Nat. Rev. Cancer 2, 740–749 (2002).

    CAS  Article  Google Scholar 

  2. 2.

    Bhagwat, A. S. & Vakoc, C. R. Trends Cancer 1, 53–65 (2015).

    Article  Google Scholar 

  3. 3.

    Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Cancer Cell 37, 496–513 (2020).

    CAS  Article  Google Scholar 

  4. 4.

    Bi, M. et al. Nat. Cell Biol. (2020).

  5. 5.

    Ross-Innes, C. S. et al. Nature 481, 389–393 (2012).

    CAS  Article  Google Scholar 

  6. 6.

    Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. Nat. Genet. 43, 27–33 (2011).

    CAS  Article  Google Scholar 

  7. 7.

    Fu, X. et al. Proc. Natl. Acad. Sci. USA 113, E6600–E6609 (2016).

    CAS  Article  Google Scholar 

  8. 8.

    Malorni, L. et al. Mol. Cancer Res. 14, 470–481 (2016).

    CAS  Article  Google Scholar 

  9. 9.

    Lupien, M. et al. Genes Dev. 24, 2219–2227 (2010).

    CAS  Article  Google Scholar 

  10. 10.

    Hiscox, S. et al. Int. J. Cancer 118, 290–301 (2006).

    CAS  Article  Google Scholar 

  11. 11.

    Jakacka, M. et al. J. Biol. Chem. 276, 13615–13621 (2001).

    CAS  Article  Google Scholar 

  12. 12.

    Chen, D. et al. Mol. Cell 6, 127–137 (2000).

    CAS  Article  Google Scholar 

  13. 13.

    Jeselsohn, R. et al. Cancer Cell 33, 173–186.e5 (2018).

    CAS  Article  Google Scholar 

  14. 14.

    Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L. & Chandarlapaty, S. Nat. Rev. Cancer 18, 662 (2018).

    CAS  Article  Google Scholar 

  15. 15.

    Guan, J. et al. Cell 178, 949–963.e18 (2019).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Christopher R. Vakoc.

Ethics declarations

Competing interests

C.R.V. has received funding from Boehringer Ingelheim and Syros Pharmaceuticals and is an advisor to KSQ Therapeutics.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wu, X.S., Vakoc, C.R. A pliable ERα cistrome evades therapy. Nat Cell Biol 22, 619–620 (2020).

Download citation


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing